Serum C-reactive protein and CRP genotype in pediatric inflammatory bowel disease: Influence on phenotype, natural history, and response to therapy

Inflammatory Bowel Diseases

Volumn 21, Issue 3, 2015, Pages 596-605

  Henderson, Paul ^a,b   Kennedy, Nicholas A ^b   Van Limbergen, Johan E ^c   Cameron, Fiona L ^b   Satsangi, Jack ^b   Russell, Richard K ^d   Wilson, David C ^a,b  

^a ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c DALHOUSIE UNIVERSITY   (Canada)

^d ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

C reactive protein; Crohn's disease; inflammatory bowel disease; pediatric; polymorphism

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; DNA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; BIOLOGICAL MARKER; TUMOR NECROSIS FACTOR;

ADOLESCENT; ARTICLE; BIOLOGICAL THERAPY; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; COLON DISEASE; CROHN DISEASE; DNA EXTRACTION; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HISTORY; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE TRAIT; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; ULCERATIVE COLITIS; ADULT; ANTAGONISTS AND INHIBITORS; BLOOD; COLITIS, ULCERATIVE; COMPARATIVE STUDY; DISEASE COURSE; GENETICS; MULTIMODALITY CANCER THERAPY; PROGNOSIS;

ADULT; AZATHIOPRINE; BIOMARKERS; C-REACTIVE PROTEIN; CHILD; COHORT STUDIES; COLITIS, ULCERATIVE; COMBINED MODALITY THERAPY; CROHN DISEASE; DISEASE PROGRESSION; FEMALE; GENOTYPE; HUMANS; MALE; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84923526727     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000296     Document Type: Article

References (57)

1. Choi YS, Hur J, Jeong S. Beta-catenin binds to the downstream region and regulates the expression C-reactive protein gene. Nucleic Acids Res. 2007; 35: 5511-5519.
2. Ganter U, Arcone R, Toniatti C, et al. Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J. 1989; 8: 3773-3779.
3. Taylor AW, Ku NO, Mortensen RF. Regulation of cytokine-induced human C-reactive protein production by transforming growth factor-beta. J Immunol. 1990; 145: 2507-2513.
4. Peyrin-Biroulet L, Gonzalez F, Dubuquoy L, et al. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut. 2012; 61: 78-85.
5. Rhodes B, Furnrohr BG, Vyse TJ. C-reactive protein in rheumatology: biology and genetics. Nat Rev Rheumatol. 2011; 7: 282-289.
6. Young DP, Kushner I, Samols D. Binding of C/EBPbeta to the C-reactive protein (CRP) promoter in Hep3B cells is associated with transcription of CRP mRNA. J Immunol. 2008; 181: 2420-2427.
7. Voleti B, Hammond DJ Jr, Thirumalai A, et al. Oct-1 acts as a transcriptional repressor on the C-reactive protein promoter. Mol Immunol. 2012; 52: 242-248.
8. Grimm AA, Brace CS, Wang T, et al. A nutrient-sensitive interaction between Sirt1 and HNF-1alpha regulates Crp expression. Aging Cell. 2011; 10: 305-317.
9. Kumar SV, Ravunny RK, Chakraborty C. Conserved domains, conserved residues, and surface cavities of C-reactive protein (CRP). Appl Biochem Biotechnol. 2011; 165: 497-505.
10. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol. 2005; 117: 104-111.
11. Weiser JN, Pan N, McGowan KL, et al. Phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae contributes to persistence in the respiratory tract and sensitivity to serum killing mediated by C-reactive protein. J Exp Med. 1998; 187: 631-640.
12. Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure. 1999; 7: 169-177.
13. Gershov D, Kim S, Brot N, et al. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med. 2000; 192: 1353-1364.
14. Tan SS, Ng PM, Ho B, et al. The antimicrobial properties of C-reactive protein (CRP). J Endotoxin Res. 2005; 11: 249-256.
15. Henderson P, Casey A, Lawrence SJ, et al. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease. Am J Gastroenterol. 2012; 107: 941-949.
16. Rezaieyazdi Z, Sahebari M, Hatef MR, et al. Is there any correlation between high sensitive CRP and disease activity in systemic lupus erythematosus. Lupus. 2011; 20: 1494-1500.
17. Yentis SM, Soni N, Sheldon J. C-reactive protein as an indicator of resolution of sepsis in the intensive care unit. Intensive Care Med. 1995; 21: 602-605.
18. Matson A, Soni N, Sheldon J. C-reactive protein as a diagnostic test of sepsis in the critically ill. Anaesth Intensive Care. 1991; 19: 182-186.
19. Turner D, Mack DR, Hyams J, et al. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both. A systematic evaluation in pediatric ulcerative colitis. J Crohns Colitis. 2011; 5: 423-429.
20. Coelho LM, Salluh JI, Soares M, et al. Patterns of c-reactive protein RATIO response in severe community-Acquired pneumonia: a cohort study. Crit Care. 2012; 16: R53.
21. Jurgens M, Mahachie John JM, Cleynen I, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2011; 9: 421-427.e1.
22. Reinisch W, Wang Y, Oddens BJ, et al. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther. 2012; 35: 568-576.
23. Thalmaier D, Dambacher J, Seiderer J, et al. The +1059G/C polymorphism in the C-reactive protein (CRP) gene is associated with involvement of the terminal ileum and decreased serum CRP levels in patients with Crohn's disease. Aliment Pharmacol Ther. 2006; 24: 1105-1115.
24. Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008; 57: 1518-1523.
25. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19(suppl A): 5-36.
26. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011; 17: 1314-1321.
27. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989; 24(suppl 170): 2-6.
28. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis\-The Porto criteria. J Pediatr Gastroenterol Nutr. 2005; 41: 1-7.
29. International HapMap Project. Database of genes associated with human disease and response to pharmaceuticals [HapMap web site]. Available at: www.hapmap.org. Accessed Jan 3, 2012.
30. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005; 21: 263-265.
31. Suk HJ, Ridker PM, Cook NR, et al. Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. Atherosclerosis. 2005; 178: 139-145.
32. Kathiresan S, Larson MG, Vasan RS, et al. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation. 2006; 113: 1415-1423.
33. Russell AI, Cunninghame Graham DS, Shepherd C, et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet. 2004; 13: 137-147.
34. Imielinski M, Baldassano RN, Griffiths A, et al. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet. 2009; 41: 1335-1340.
35. Johnson AD, Handsaker RE, Pulit SL, et al. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics. 2008; 24: 2938-2939.
36. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16: 1215.
37. Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008; 135: 1114-1122.
38. Turner D, Griffiths AM, Walters TD, et al. Appraisal of the pediatric Crohn's disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties. Am J Gastroenterol. 2010; 105: 2085-2092.
39. Russell RK, Wilson ML, Loganathan S, et al. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther. 2011; 33: 946-953.
40. Cameron FL, Wilson ML, Basheer N, et al. Anti-TNF therapy for paediatric IBD: the Scottish national experience. Arch Dis Child. [epub ahead of print].
41. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007; 133: 423-432.
42. Sole X, Guino E, Valls J, et al. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006; 22: 1928-1929.
43. Henderson P, Hansen R, Cameron FL, et al. Rising incidence of pediatric inflammatory bowel disease in Scotland. Inflamm Bowel Dis. 2012; 18: 999-1005.
44. Henderson P, Rogers P, Mitchell D, et al. The epidemiology and natural history of paediatric inflammatory bowel disease in Southeast Scotland: a prospective 13-year study. Gut. 2011; 60(suppl 3): A62.
45. Lange LA, Carlson CS, Hindorff LA, et al. Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA. 2006; 296: 2703-2711.
46. Kravitz MS, Pitashny M, Shoenfeld Y. Protective molecules-C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannosebinding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: prevalence and clinical significance in autoimmunity. J Clin Immunol. 2005; 25: 582-591.
47. Sandborn WJ, Colombel JF, Castillo MM, et al. Elevated C-reactive protein in anti-TNF-naive patients is associated with higher remission rates. Gut. 2011; 60(suppl 3): A195.
48. Willot S, Vermeire S, Ohresser M, et al. No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease. Pharmacogenet Genomics. 2006; 16: 37-42.
49. Quail MA, Russell RK, Van Limbergen JE, et al. Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15: 756-759.
50. Buchanan E, Gaunt WW, Cardigan T, et al. The use of exclusive enteral nutrition for induction of remission in children with Crohn's disease demonstrates that disease phenotype does not influence clinical remission. Aliment Pharmacol Ther. 2009; 30: 501-507.
51. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004; 350: 1387-1397.
52. Wensley F, Gao P, Burgess S, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011; 342: d548.
53. Tilakaratne S, Lemberg DA, Leach ST, et al. C-reactive protein and disease activity in children with Crohn's disease. Dig Dis Sci. 2010; 55: 131-136.
54. Toedter GP, Blank M, Lang Y, et al. Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. Am J Gastroenterol. 2009; 104: 2768-2773.
55. Kruis W, Katalinic A, Klugmann T, et al. Predictive factors for an uncomplicated long-term course of Crohn's disease: a retrospective analysis. J Crohns Colitis. 2013; 7: e263-70.
56. Kiss LS, Papp M, Lovasz BD, et al. High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: a marker for patient classification. Inflamm Bowel Dis. 2012; 18: 1647-1654.
57. Markowitz J. Early inflammatory bowel disease: different treatment response to specific or all medications. Dig Dis. 2009; 27: 358-365.